Influx Healthtech Delivers Robust H1 FY27 Growth with Expanding CDMO Capacities
Influx Healthtech Ltd · Investor Presentation · 05 Nov 2026, 6:01 pm
Influx Healthtech Delivers Robust H1 FY27 Growth with Expanding CDMO Capacities Influx Healthtech reported H1 FY27 revenue of ₹85.4 cr, up 27.9% YoY, driven primarily by nutraceuticals (88% mix). EBITDA rose 25.1% YoY to ₹18.3 cr with a 21.5% margin, while PAT expanded 20.0% YoY to ₹12.0 cr (14.1% margin). Annualized RoE and RoCE reached 21.4% and 28.1%, respectively, backed by a zero-debt balance sheet. The company targets 25% growth in FY27, supported by ongoing commercialization at its new 75,000 sq. ft. Palghar facility, automated line additions, and an expected 2.5x capacity expansion post-IPO proceeds utilization.
Original exchange filing (PDF)
More announcements from Influx Healthtech Ltd
- Influx Healthtech Limited has informed the Exchange about Transcript of Investor Conference call held on November 5, 2026 · 09 Nov 2026
- Influx Healthtech Limited has informed the Exchange about Link of Recording of Investor Conference Call held on November 5, 2026 · 05 Nov 2026
- Influx Healthtech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Influx Healthtech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
- Influx Healthtech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
- Influx Healthtech Limited has informed the Exchange about Schedule of Investor Conference Call · 05 Nov 2026
- INFLUX HEALTHTECH LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 04 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 04 Nov 2026
